Table of Contents
- Your Partner in Medical Weight Loss: Slinic
- Understanding Wegovy and the Necessity of Clinical Eligibility
- The Core Wegovy Eligibility Criteria: BMI and Health Markers
- NHS vs. Private Wegovy Access: Navigating Your Options
- Clinical Exclusions: Who Should NOT Use Wegovy?
- The Slinic Approach: Your Journey from Assessment to Treatment
- Frequently Asked Questions
Your Partner in Medical Weight Loss: Slinic
Slinic is a UK-based, GPhC Registered Pharmacy (No. 1033729) specialising in clinically supervised weight-loss treatments. Led by a dedicated team of registered Pharmacists and Prescribing Doctors, we provide a safe, regulated, and supportive pathway to medical weight loss. Our "safety-first" approach is built on robust eligibility assessments, documented protocols, and continuous monitoring to ensure your health is always the primary focus. We combine high professional accountability with the convenience of discreet nationwide delivery, offering fast access to evidence-based treatments like Wegovy and Mounjaro.
Begin Your Journey Today
Ready to find out if you qualify for a medical weight loss treatment? Complete our comprehensive clinical assessment to receive a personalised plan from a registered UK prescriber.
Start Your Clinical Weight Loss Assessment with Slinic Today
- Regulated & Accountable: Fully regulated by the General Pharmaceutical Council (GPhC No. 1033729).
- Clinician-Led: Care plans are developed and monitored by registered Pharmacists and Prescribing Doctors.
- Trusted & Discreet: Competitive UK pricing with fast, temperature-controlled delivery to your door.
Understanding Wegovy and the Necessity of Clinical Eligibility
Wegovy (semaglutide) is a prescription-only GLP-1 receptor agonist licensed for chronic weight management. It is a powerful medical tool, not a cosmetic solution, which is why strict eligibility criteria are essential. These clinical standards, guided by NICE (National Institute for Health and Care Excellence), ensure the medication is used safely and effectively by individuals who stand to gain the most significant health benefits.
At Slinic, we view eligibility as the first and most critical step in our approach to sustainable, long-term health. It is a clinical safety framework designed to protect you, ensuring that this weight loss treatment is the right biological foundation for your health journey.
The Role of Semaglutide in Weight Management
Semaglutide, the active ingredient in Wegovy, works by mimicking a natural gut hormone (GLP-1). This action helps to regulate your appetite, reduce hunger signals, and slow the speed at which your stomach empties, making you feel fuller for longer. Because of its potent effects on the body’s metabolic systems, a thorough clinical assessment is required to differentiate its use from a simple "lifestyle" diet. Wegovy is most effective when used as part of a structured medical weight loss plan that includes guidance on diet, nutrition, and physical activity.
UK Regulatory Standards for Weight Loss Injections
In the UK, the supply of prescription medications like Wegovy is strictly overseen by the Medicines and Healthcare products Regulatory Agency (MHRA) and the General Pharmaceutical Council (GPhC). This robust governance means that Wegovy is not available over-the-counter and can only be supplied following a private prescription from a registered prescriber. This ensures every patient undergoes a proper clinical evaluation to confirm their suitability and to establish a safe treatment protocol.
The Core Wegovy Eligibility Criteria: BMI and Health Markers
The primary metric for determining Wegovy eligibility is the Body Mass Index (BMI), a measure of your weight in relation to your height. However, it is not just a single number; it is part of a wider clinical picture our prescribers assess to ensure patient safety and treatment efficacy.
- A BMI of 30 kg/m² or above (classified as obese) is the standard threshold.
- A BMI between 27 kg/m² and 29.9 kg/m² (classified as overweight) may also qualify if you have at least one diagnosed weight-related comorbidity.
Our clinicians conduct a meticulous review of these markers, because your long-term health is our foremost priority.
Defining Weight-Related Comorbidities
A comorbidity is a pre-existing health condition that is caused or worsened by excess weight. The presence of such a condition indicates a higher level of health risk, which is why the BMI threshold for Wegovy is lowered to 27 kg/m² for these patients. Common qualifying conditions include:
- Type 2 diabetes
- Hypertension (high blood pressure)
- Dyslipidaemia (e.g., high cholesterol)
- Obstructive sleep apnoea
- Cardiovascular disease (e.g., history of heart attack or stroke)
Ethnicity-Adjusted BMI Thresholds
Clinical evidence shows that individuals from certain minority ethnic backgrounds are at a significantly higher risk of developing metabolic health conditions like Type 2 diabetes at a lower BMI. In line with NICE recommendations, our clinicians apply lower BMI thresholds for eligibility, typically reducing the standard figures by 2.5 points. This ensures more equitable and clinically appropriate access for people of:
- South Asian
- Chinese
- Black African
- African-Caribbean descent
Age and Developmental Requirements
In the UK, Wegovy is licensed for adults aged 18 and over. While there is no strict upper age limit, our prescribers give special consideration to elderly patients, carefully evaluating factors like muscle mass, kidney function, and potential medication interactions. Paediatric use is highly restricted and only occurs within specialist NHS services.
NHS vs. Private Wegovy Access: Navigating Your Options
Accessing Wegovy in the UK can be done via two distinct routes: the NHS or a private clinic like Slinic. While both pathways adhere to the same fundamental medical eligibility criteria to ensure safety, the access requirements, waiting times, and overall experience differ significantly.
| Feature | NHS Pathway | Private Clinic (Slinic) |
|---|---|---|
| Access Point | GP referral to a Tier 3 Specialist Weight Management Service. | Direct access via a comprehensive online clinical assessment. |
| Wait Times | Often extensive, with long waiting lists for specialist services. | Fast access to professional support, often within days. |
| BMI Criteria | Typically stricter: BMI of 35+ (or 30+ with specific comorbidities). | Follows NICE guidelines: BMI of 30+ (or 27+ with comorbidities). |
| Treatment Duration | Capped at a maximum of two years. | Ongoing, based on clinical progress and mutual agreement. |
| Cost | Covered by the NHS prescription charge (if applicable). | Self-funded, with clear pricing for medication and clinical services. |
The NHS Tier 3 Pathway
To be considered for Wegovy on the NHS, you must first be referred by your GP to a multidisciplinary Tier 3 specialist team. This service is designed for individuals with complex obesity-related needs. The criteria are often more stringent than the manufacturer’s licence, and treatment is limited to a two-year cycle.
The Private Clinic Experience at Slinic
Slinic provides a streamlined, clinically robust alternative. Our online pharmacy consultation allows you to bypass long NHS waiting lists and receive a prompt eligibility decision from a UK-registered prescriber. We uphold the highest standards of clinical governance, ensuring your assessment is just as thorough as an in-person consultation, while offering the convenience and competitive UK pricing of a digital-first service.
Clinical Exclusions: Who Should NOT Use Wegovy?
Determining eligibility is as much about identifying who should receive treatment as it is about identifying who should not. Our stringent safety netting protocols are designed to protect patients for whom semaglutide could pose a significant health risk. If our prescribers identify any of the following contraindications in your medical history, you will be deemed not eligible for treatment.
Absolute Contraindications and Safety Exclusions
A personal or family history of certain rare conditions means Wegovy is not a safe option for you. These include:
- Medullary Thyroid Carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A previous history of acute or chronic pancreatitis
Pregnancy, Breastfeeding, and Fertility
Wegovy is strictly contraindicated during pregnancy and breastfeeding. Due to its long half-life, the medication must be discontinued at least two months before a planned pregnancy to ensure it is fully cleared from your system. Our clinicians will provide clear safety protocols for all female patients of childbearing age.
Interactions with Other Medications
Your safety depends on full transparency. It is vital you disclose all current medications during your weight loss assessment. Specific risks include:
- Combining Wegovy with other GLP-1 medications (like Saxenda or Ozempic) or insulin can increase the risk of hypoglycaemia.
- As semaglutide slows stomach emptying, it can affect the absorption of oral medications taken at the same time.
The Slinic Approach: Your Journey from Assessment to Treatment
Our entire process is designed to be safe, transparent, and supportive. From your initial assessment to ongoing care, our clinical team is here to guide you.
Completing Your Online Clinical Assessment
Your journey begins with our comprehensive, audit-ready digital consultation. You will be asked to provide your current weight, height, and a detailed medical history. To verify your identity and ensure patient safety, we require a photo ID or a clear "selfie". This information is not just a tick-box exercise; our clinicians use this data to build a complete picture of your health and create a bespoke weight loss treatment plan.
What Happens After Approval?
Once a Slinic prescriber has approved your treatment, you will transition from the eligibility check to starting your first dose of 0.25mg semaglutide. Your Wegovy pens will be dispatched via discreet, temperature-controlled delivery. You will also gain access to our extensive treatment guides covering everything from injection technique to managing side effects. Our commitment to you doesn’t end there; we provide structured follow-up and ongoing clinical support to ensure your medical weight loss journey is both safe and effective. We will also help you manage the Wegovy titration schedule as you progress.
Frequently Asked Questions
Can I get Wegovy if my BMI is exactly 27?
You may be eligible if your BMI is 27 kg/m² or higher, provided you also have a qualifying weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol. Our clinicians will assess this during your consultation.
Does the NHS provide Wegovy for free to everyone who is eligible?
No. Wegovy is available on the NHS but only through specialist Tier 3 weight management services, which have very strict criteria (often a BMI of 35+) and long waiting lists. It is not available as a routine prescription from a GP.
What medical evidence do I need to provide for a private Wegovy prescription?
You do not need to provide documents. You simply need to complete our detailed online assessment, where you will declare your medical history, current health status, weight, and height. We also require a form of photo ID to verify your identity for safety and regulatory purposes.
Will I be eligible for Wegovy if I have Type 1 Diabetes?
Wegovy is not licensed for patients with Type 1 diabetes. It is generally considered a contraindication due to the potential risk of diabetic ketoacidosis. Patient safety is our priority, and we do not prescribe in these circumstances.
Can I switch from Mounjaro to Wegovy if I meet the criteria for both?
Yes, it is possible to switch between weight loss injections like Mounjaro and Wegovy. However, this must be carefully managed by a clinician to ensure there is an appropriate "washout" period between treatments to prevent adverse effects. Our team can provide guidance on this.
What happens if I lose enough weight that my BMI falls below the eligibility threshold?
This is a positive outcome and the primary goal of the treatment. Our clinical team will regularly review your progress. When you reach your health goals, we will discuss a sustainable maintenance plan, which may involve adjusting your dose or safely discontinuing the medication.
Is there an upper age limit for Wegovy eligibility in the UK?
There is no official upper age limit. However, our prescribers conduct a particularly thorough assessment for elderly patients, taking into account factors like kidney function, muscle mass, and other existing health conditions to ensure the treatment is safe and appropriate.
How often is my eligibility reviewed once I start the treatment?
Your eligibility and progress are reviewed continuously. We use structured follow-ups and patient check-ins to monitor your health, manage side effects, and ensure the treatment remains both safe and effective for you throughout your journey.
Take the Next Step with Confidence
Our UK-registered clinical team is ready to help you explore your options for medical weight loss. Start your confidential assessment today to see if Wegovy is the right choice for you.
Start Your Clinical Weight Loss Assessment with Slinic Today
